Eli Lilly - Biotech Market Share Report

Eli Lilly market share report graphic featuring Eli Lilly, Humalog, Forteo and Xigris logosCompany: Eli Lilly
2007 Sales: $3.9 billion
Market share: 5.2%
CAGR: 4.7%

What they have: Eli Lilly has only one biologic blockbuster, despite the fact that it ranks fifth in overall biologic sales. Humalog, a Type 1 and 2 diabetes treatment, brought in $1.5 billion in sales in 2007. The company's big sellers include Forteo, a synthetic form of the natural occurring hormone that treats osteoporosis in men and women, and Xigris, a treatment for sepsis. About 25 percent of Lilly's 2007 sales came from biotech medicines.

What to look for: Biotech molecules also represent approximately one-third of the Lilly's current pipeline, including potential treatments targeting Alzheimer's disease, cancer and diabetes, according to a recent release. Lilly is working with MacroGenics to develop teplizumab, a humanized anti-CD3 monoclonal antibody for Type 1 diabetes which is in Phase III trials. The company is also partnered with Canadian biotech BioMS to develop dirucotide, a multiple sclerosis treatment. Many of the company's other biotech drugs are in Phase I or II trials

Eli Lilly - Biotech Market Share Report

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i